Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 4Completed 1Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 5

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 6CNS 2

Conditions

Melanoma 6Brain Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 262Specimen Handling 253pembrolizumab 230Cyclophosphamide 216Radiotherapy 204Nivolumab 168Cisplatin 161Carboplatin 145Biopsy 144Radiosurgery 128fludarabine 123Blood Specimen Collection 116Gemcitabine 111Paclitaxel 107Surveys and Questionnaires 106Standard of Care 102venetoclax 94Dexamethasone 93Bevacizumab 92Radiation 87Rituximab 81Capecitabine 80Cytarabine 79Oxaliplatin 77Drug Therapy 75Doxorubicin 75Ipilimumab 73durvalumab 70fludarabine phosphate 69atezolizumab 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Opdualag × 90 days × Clear all
NCT06319196 2026-06-04

ClearMe

University Health Network, Toronto

Phase 2 Recruiting
54 enrolled
Dermatologic

Melanoma

NCT05912244 2026-06-01

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
43 enrolled
Dermatologic

Melanoma

NCT07281924 2026-05-29

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

University of Wisconsin, Madison

Phase 1/2 Recruiting
15 enrolled
Dermatologic

Melanoma

NCT06712927 2026-05-18

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Stanford University

Phase 2 Recruiting
60 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT05704933 2026-04-06

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
1 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT06295159 2026-04-01

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
90 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡